Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics

Virology

Volumn 377, Issue 1, 2008, Pages 170-183

  Nelson, Josh D ^a   Kinkead, Heather ^a   Brunel, Florence M ^a   Leaman, Dan ^a   Jensen, Richard ^a   Louis, John M ^b   Maruyama, Toshiaki ^e   Bewley, Carole A ^c   Bowdish, Katherine ^e   Clore, G Marius ^b   Dawson, Philip E ^a   Frederickson, Shana ^e   Mage, Rose G ^d   Richman, Douglas D ^f   Burton, Dennis R ^a   Zwick, Michael B ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e Alexion Antibody Technologies Inc   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody neutralization; Epitope exposure; Fusion intermediate; HIV 1 gp41; Phage display; Six helix bundle; Vaccine design; Virus capture

Indexed keywords

CARDIOLIPIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 8K8; MONOCLONAL ANTIBODY D5; MONOCLONAL ANTIBODY DN9; PROTEIN GP41; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; COILED BODY; CONTROLLED STUDY; DRUG BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE LIBRARY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, MONOCLONAL; BINDING SITES; CARDIOLIPINS; CROSS REACTIONS; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MOLECULAR MIMICRY; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PROTEIN STRUCTURE, TERTIARY; RABBITS; REPETITIVE SEQUENCES, AMINO ACID; SEQUENCE HOMOLOGY, AMINO ACID;

HUMAN IMMUNODEFICIENCY VIRUS 1; ORYCTOLAGUS CUNICULUS;

EID: 46549086533     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.04.005     Document Type: Article

References (104)

1. Barbas III C.F., Burton D.R., Scott J.K., and Silverman G.J. Phage Display: A Laboratory Manual (2001), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York
2. Beddows S., Franti M., Dey A.K., Kirschner M., Iyer S.P., Fisch D.C., Ketas T., Yuste E., Desrosiers R.C., Klasse P.J., Maddon P.J., Olson W.C., and Moore J.P. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 360 2 (2007) 329-340
3. Bianchi E., Finotto M., Ingallinella P., hrin R., Carella A.V., Hou X.S., Schleif W.A., Miller M.D., Geleziunas R., and Pessi A. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Proc. Natl. Acad. Sci. U. S. A 102 36 (2005) 12903-12908
4. Binley J.M., Ditzel H.J., Barbas III C.F., Sullivan N., Sodroski J., Parren P.W., and Burton D.R. Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. AIDS Res. Hum. Retrovir. 12 10 (1996) 911-924
5. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., and Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78 (2004) 13232-13252
6. Bjorndal A., Deng H., Jansson M., Fiore J.R., Colognesi C., Karlsson A., Albert J., Scarlatti G., Littman D.R., and Fenyo E.M. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71 10 (1997) 7478-7487
7. Buchacher A., Predl R., Strutzenberger K., Steinfellner W., Trkola A., Purtscher M., Gruber G., Tauer C., Steindl F., Jungbauer A., et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retrovir. 10 4 (1994) 359-369
8. Burrer R., Haessig-Einius S., Aubertin A.M., and Moog C. Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41. Virology 333 1 (2005) 102-113
9. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., Sawyer L.S., Hendry R.M., Dunlop N., Nara P.L., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266 5187 (1994) 1024-1027
10. Caffrey M., Cai M., Kaufman J., Stahl S.J., Wingfield P.T., Covell D.G., Gronenborn A.M., and Clore G.M. Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J 17 16 (1998) 4572-4584
11. Calarese D.A., Scanlan C.N., Zwick M.B., Deechongkit S., Mimura Y., Kunert R., Zhu P., Wormald M.R., Stanfield R.L., Roux K.H., Kelly J.W., Rudd P.M., Dwek R.A., Katinger H., Burton D.R., and Wilson I.A. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300 5628 (2003) 2065-2071
12. Chan D.C., Fass D., Berger J.M., and Kim P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89 2 (1997) 263-273
13. Chan D.C., Chutkowski C.T., and Kim P.S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. U. S. A 95 26 (1998) 15613-15617
14. Chang D.K., and Hsu C.S. Biophysical evidence of two docking sites of the carboxyl heptad repeat region within the amino heptad repeat region of gp41 of human immunodeficiency virus type 1. Antivir. Res. 74 1 (2007) 51-58
15. Chen C.H., Greenberg M.L., Bolognesi D.P., and Matthews T.J. Monoclonal antibodies that bind to the core of fusion-active glycoprotein 41. AIDS Res. Hum. Retrovir. 16 18 (2000) 2037-2041
16. Chen B., Vogan E.M., Gong H., Skehel J.J., Wiley D.C., and Harrison S.C. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433 7028 (2005) 834-841
17. Cheng-Mayer C., Liu R., Landau N.R., and Stamatatos L. Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor. J. Virol. 71 2 (1997) 1657-1661
18. Choudhry V., Zhang M.Y., Harris I., Sidorov I.A., Vu B., Dimitrov A.S., Fouts T., and Dimitrov D.S. Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem. Biophys. Res. Commun. 348 3 (2006) 1107-1115
19. Choudhry V., Zhang M.Y., Sidorov I.A., Louis J.M., Harris I., Dimitrov A.S., Bouma P., Cham F., Choudhary A., Rybak S.M., Fouts T., Montefiori D.C., Broder C.C., Quinnan Jr. G.V., and Dimitrov D.S. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 363 1 (2007) 79-90
20. Connor R.I., Chen B.K., Choe S., and Landau N.R. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206 2 (1995) 935-944
21. Crooks E.T., Moore P.L., Franti M., Cayanan C.S., Zhu P., Jiang P., deVries R., Wiley C., Zharkikh I., Schülke N., Roux K.H., Montefiori D.C., Burton D.R., and Binley J.M. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 366 2 (2007) 245-262
22. Dhillon A.K., Donners H., Pantophlet R., Johnson W.E., Decker J.M., Shaw G.M., Lee F.H., Richman D.D., Doms R.W., Vanham G., and Burton D.R. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from HIV-1 infected donors. J. Virol. 81 (2007) 6548-6562
23. Dimitrov A.S., Louis J.M., Bewley C.A., Clore G.M., and Blumenthal R. Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation. Biochemistry 44 37 (2005) 12471-12479
24. Dimitrov A.S., Jacobs A., Finnegan C.M., Stiegler G., Katinger H., and Blumenthal R. Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. Biochemistry 46 5 (2007) 1398-1401
25. Dwyer J.J., Hasan A., Wilson K.L., White J.M., Matthews T.J., and Delmedico M.K. The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation. Biochemistry 42 17 (2003) 4945-4953
26. Earl P.L., Broder C.C., Doms R.W., and Moss B. Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J. Virol. 71 4 (1997) 2674-2684
27. Eckert D.M., and Kim P.S. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc. Natl. Acad. Sci. U. S. A 98 20 (2001) 11187-11192
28. Eckert D.M., and Kim P.S. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70 (2001) 777-810
29. Eckert D.M., Malashkevich V.N., Hong L.H., Carr P.A., and Kim P.S. Inhibiting HIV-1 entry: discovery of d-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99 1 (1999) 103-115
30. Gorny M.K., and Zolla-Pazner S. Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41. J. Virol. 74 13 (2000) 6186-6192
31. Grundner C., Li Y., Louder M., Mascola J., Yang X., Sodroski J., and Wyatt R. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins. Virology 331 1 (2005) 33-46
32. Gustchina E., Hummer G., Bewley C.A., and Clore G.M. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV. J. Med. Chem. 48 8 (2005) 3036-3044
33. Gustchina E., Louis J.M., Lam S.N., Bewley C.A., and Clore G.M. A Monoclonal Fab derived from a human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains. J. Virol. 81 23 (2007) 12946-12953
34. Hamburger A.E., Kim S., Welch B.D., and Kay M.S. Steric accessibility of the HIV-1 gp41 N-trimer region. J. Biol. Chem. 280 13 (2005) 12567-12572
35. Harris E.N., Pierangeli S., and Birch D. Anticardiolipin wet workshop report. Fifth International Symposium on antiphospholipid antibodies. Am. J. Clin. Pathol. 101 5 (1994) 616-624
36. Hartley O., Klasse P.J., Sattentau Q., and Moore J.P. V3: HIV-1's switch-hitter. AIDS Res. Hum. Retrovir. 21 (2005) 171-189
37. Haynes B.F., Fleming J., St Clair W.E., Katinger H., Stiegler G., Kunert R., Robinson J., Scearce R.M., Plonk K., Staats H.F., Ortel T.L., Liao H.X., and Alam M.S. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308 (2005) 1906-1908
38. Huang C.C., Tang M., Zhang M.Y., Majeed S., Montabana E., Stanfield R.L., Dimitrov D.S., Korber B., Sodroski J., Wilson I.A., Wyatt R., and Kwong P.D. Structure of a V3-containing HIV-1 gp120 core. Science 310 5750 (2005) 1025-1028
39. Hwang K.K., Grossman J.M., Visvanathan S., Chukwuocha R.U., Woods Jr. V.L., Le D.T., Hahn B.H., and Chen P.P. Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. J. Immunol. 167 12 (2001) 7192-7198
40. Jiang S., Lin K., Strick N., and Neurath A.R. HIV-1 inhibition by a peptide. Nature 365 6442 (1993) 113
41. Jiang S., Lin K., and Lu M. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J. Virol. 72 12 (1998) 10213-10217
42. Ketas T.J., Kuhmann S.E., Palmer A., Zurita J., He W., Ahuja S.K., Klasse P.J., and Moore J.P. Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology 364 2 (2007) 281-290
43. Kim Y.B., Han D.P., Cao C., and Cho M.W. Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies. Virology 305 1 (2003) 124-137
44. Kim M., Qiao Z., Yu J., Montefiori D., and Reinherz E.L. Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state. Vaccine 25 27 (2007) 5102-5114
45. Kirschner M., Monrose V., Paluch M., Techodamrongsin N., Rethwilm A., and Moore J.P. The production of cleaved, trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein vaccine antigens and infectious pseudoviruses using linear polyethylenimine as a transfection reagent. Protein Expr. Purif. 48 1 (2006) 61-68
46. Klausner R.D., Fauci A.S., Corey L., Nabel G.J., Gayle H., Berkley S., Haynes B.F., Baltimore D., Collins C., Douglas R.G., Esparza J., Francis D.P., Ganguly N.K., Gerberding J.L., Johnston M.I., Kazatchkine M.D., McMichael A.J., Makgoba M.W., Pantaleo G., Piot P., Shao Y., Tramont E., Varmus H., and Wasserheit J.N. Medicine. The need for a global HIV vaccine enterprise. Science 300 5628 (2003) 2036-2039
47. Labrijn A.F., Poignard P., Raja A., Zwick M.B., Delgado K., Franti M., Binley J., Vivona V., Grundner C., Huang C.C., Venturi M., Petropoulos C.J., Wrin T., Dimitrov D.S., Robinson J., Kwong P.D., Wyatt R.T., Sodroski J., and Burton D.R. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 77 19 (2003) 10557-10565
48. Law M., Cardoso R.M., Wilson I.A., and Burton D.R. Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. J. Virol. 81 8 (2007) 4272-4285
49. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., and Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79 16 (2005) 10108-10125
50. Louis J.M., Bewley C.A., and Clore G.M. Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. J. Biol. Chem. 276 31 (2001) 29485-29489
51. Louis J.M., Nesheiwat I., Chang L., Clore G.M., and Bewley C.A. Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J. Biol. Chem. 278 22 (2003) 20278-20285
52. Louis J.M., Bewley C.A., Gustchina E., Aniana A., and Clore G.M. Characterization and HIV-1 fusion inhibitory properties of monoclonal Fabs obtained from a human non-immune phage library selected against diverse epitopes of the ectodomain of HIV-1 gp41. J. Mol. Biol. 353 5 (2005) 945-951
53. Lu M., Blacklow S.C., and Kim P.S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2 12 (1995) 1075-1082
54. Luftig M.A., Mattu M., Di Giovine P., Geleziunas R., hrin R., Barbato G., Bianchi E., Miller M.D., Pessi A., and Carfi A. Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nat. Struct. Biol. 13 8 (2006) 740-747
55. McBurney S.P., Young K.R., and Ross T.M. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology 358 2 (2007) 334-346
56. McMichael A.J. HIV vaccines. Annu. Rev. Immunol. 24 (2006) 227-255
57. Melikyan G.B., Markosyan R.M., Hemmati H., Delmedico M.K., Lambert D.M., and Cohen F.S. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J. Cell Biol. 151 2 (2000) 413-423
58. Miller M.D., Geleziunas R., Bianchi E., Lennard S., hrin R., Zhang H., Lu M., An Z., Ingallinella P., Finotto M., Mattu M., Finnefrock A.C., Bramhill D., Cook J., Eckert D.M., Hampton R., Patel M., Jarantow S., Joyce J., Ciliberto G., Cortese R., Lu P., Strohl W., Schleif W., McElhaugh M., Lane S., Lloyd C., Lowe D., Osbourn J., Vaughan T., Emini E., Barbato G., Kim P.S., Hazuda D.J., Shiver J.W., and Pessi A. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc. Natl. Acad. Sci. U. S. A 102 41 (2005) 14759-14764
59. Moore J.P., Cao Y., Leu J., Qin L., Korber B., and Ho D.D. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J. Virol. 70 1 (1996) 427-444
60. Moore P.L., Crooks E.T., Porter L., Zhu P., Cayanan C.S., Grise H., Corcoran P., Zwick M.B., Franti M., Morris L., Roux K.H., Burton D.R., and Binley J.M. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J. Virol. 80 5 (2006) 2515-2528
61. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Ruker F., and Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67 11 (1993) 6642-6647
62. Nelson J.D., Brunel F.M., Jensen R., Crooks E.T., Cardoso R.M., Wang M., Hessell A., Wilson I.A., Binley J.M., Dawson P.E., Burton D.R., and Zwick M.B. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J. Virol. 81 8 (2007) 4033-4043
63. Nyambi P.N., Mbah H.A., Burda S., Williams C., Gorny M.K., Nadas A., and Zolla-Pazner S. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J. Virol. 74 15 (2000) 7096-7107
64. Opalka D., Pessi A., Bianchi E., Ciliberto G., Schleif W., McElhaugh M., Danzeisen R., Geleziunas R., Miller M., Eckert D.M., Bramhill D., Joyce J., Cook J., Magilton W., Shiver J., Emini E., and Esser M.T. Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay. J. Immunol. Methods 287 1-2 (2004) 49-65
65. Pantophlet R., and Burton D.R. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24 (2006) 739-769
66. Parren P.W., Wang M., Trkola A., Binley J.M., Purtscher M., Katinger H., Moore J.P., and Burton D.R. Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. J. Virol. 72 12 (1998) 10270-10274
67. Peden K., Emerman M., and Montagnier L. Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology 185 2 (1991) 661-672
68. Phogat S., and Wyatt R. Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Curr. Pharm. Des. 13 2 (2007) 213-227
69. Poignard P., Moulard M., Golez E., Vivona V., Franti M., Venturini S., Wang M., Parren P.W., and Burton D.R. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J. Virol. 77 1 (2003) 353-365
70. Popkov M., Mage R.G., Alexander C.B., Thundivalappil S., Barbas III C.F., and Rader C. Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display. J. Mol. Biol. 325 2 (2003) 325-335
71. Quinnan Jr. G.V., Zhang P.F., Fu D.W., Dong M., and Alter H.J. Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response. AIDS Res. Hum. Retrovir. 15 6 (1999) 561-570
72. Reeves J.D., Gallo S.A., Ahmad N., Miamidian J.L., Harvey P.E., Sharron M., Pohlmann S., Sfakianos J.N., Derdeyn C.A., Blumenthal R., Hunter E., and Doms R.W. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl. Acad. Sci. U. S. A 99 25 (2002) 16249-16254
73. Reeves J.D., Lee F.H., Miamidian J.L., Jabara C.B., Juntilla M.M., and Doms R.W. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J. Virol. 79 8 (2005) 4991-4999
74. Root M.J., Kay M.S., and Kim P.S. Protein design of an HIV-1 entry inhibitor. Science 291 5505 (2001) 884-888
75. Sattentau Q.J., Zolla-Pazner S., and Poignard P. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 206 1 (1995) 713-717
76. Scherer E.M., Zwick M.B., Teyton L., and Burton D.R. Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS 21 (2007) 2131-2139
77. Selvarajah S., Puffer B., Pantophlet R., Law M., Doms R.W., and Burton D.R. Comparing antigenicity and immunogenicity of engineered gp120. J. Virol. 79 19 (2005) 12148-12163
78. Sia S.K., and Kim P.S. Protein grafting of an HIV-1-inhibiting epitope. Proc. Natl. Acad. Sci. U. S. A 100 17 (2003) 9756-9761
79. Sougrat R., Bartesaghi A., Lifson J.D., Bennett A.E., Bess J.W., Zabransky D.J., and Subramaniam S. Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry. PLoS Pathog. 3 5 (2007) e63
80. Srivastava I.K., Ulmer J.B., and Barnett S.W. Role of neutralizing antibodies in protective immunity against HIV. Hum. Vaccine 1 2 (2005) 45-60
81. Stamatatos L., Lim M., and Cheng-Mayer C. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates. AIDS Res. Hum. Retrovir. 16 10 (2000) 981-994
82. Steger H.K., and Root M.J. Kinetic dependence to HIV-1 entry inhibition. J Biol Chem 281 35 (2006) 25813-25821
83. Stiegler G., Kunert R., Purtscher M., Wolbank S., Voglauer R., Steindl F., and Katinger H. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retrovir. 17 18 (2001) 1757-1765
84. Sullivan N., Sun Y., Sattentau Q., Thali M., Wu D., Denisova G., Gershoni J., Robinson J., Moore J., and Sodroski J. CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J. Virol. 72 6 (1998) 4694-4703
85. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J.P., and Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70 2 (1996) 1100-1108
86. Vcelar B., Stiegler G., Wolf H.M., Muntean W., Leschnik B., Mehandru S., Markowitz M., Armbruster C., Kunert R., Eibl M.M., and Katinger H. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS 21 16 (2007) 2161-2170
87. Vujcic L.K., and Quinnan Jr. G.V. Preparation and characterization of human HIV type 1 neutralizing reference sera. AIDS Res. Hum. Retrovir. 11 7 (1995) 783-787
88. Weissenhorn W., Dessen A., Harrison S.C., Skehel J.J., and Wiley D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387 6631 (1997) 426-430
89. Welch B.D., VanDemark A.P., Heroux A., Hill C.P., and Kay M.S. Potent d-peptide inhibitors of HIV-1 entry. Proc. Natl. Acad. Sci. U. S. A 104 43 (2007) 16828-16833
90. Wild C.T., Shugars D.C., Greenwell T.K., McDanal C.B., and Matthews T.J. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U. S. A 91 21 (1994) 9770-9774
91. Wild M.A., Xin H., Maruyama T., Nolan M.J., Calveley P.M., Malone J.D., Wallace M.R., and Bowdish K.S. Human antibodies from immunized donors are protective against anthrax toxin in vivo. Nat. Biotechnol. 21 11 (2003) 1305-1306
92. Wu T.T., Johnson G., and Kabat E.A. Length distribution of CDRH3 in antibodies. Proteins 16 1 (1993) 1-7
93. Wyatt R., and Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280 5371 (1998) 1884-1888
94. Xu J.Y., Gorny M.K., Palker T., Karwowska S., and Zolla-Pazner S. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J. Virol. 65 9 (1991) 4832-4838
95. Yang X., Wyatt R., and Sodroski J. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J. Virol. 75 3 (2001) 1165-1171
96. Zanetti G., Briggs J.A., Grunewald K., Sattentau Q.J., and Fuller S.D. Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathog. 2 8 (2006) e83
97. Zhang M.Y., Choudhry V., Sidorov I.A., Tenev V., Vu B.K., Choudhary A., Lu H., Stiegler G.M., Katinger H.W., Jiang S., Broder C.C., and Dimitrov D.S. Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning. J. Immunol. Methods 317 1-2 (2006) 21-30
98. Zhou T., Xu L., Dey B., Hessell A.J., Van Ryk D., Xiang S.H., Yang X., Zhang M.Y., Zwick M.B., Arthos J., Burton D.R., Dimitrov D.S., Sodroski J., Wyatt R., Nabel G.J., and Kwong P.D. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445 7129 (2007) 732-737
99. Zhu P., Liu J., Bess Jr. J., Chertova E., Lifson J.D., Grise H., Ofek G.A., Taylor K.A., and Roux K.H. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441 (2006) 847-852
100. Zwick M.B. The membrane-proximal external region of HIV-1 gp41: a vaccine target worth exploring. AIDS 19 16 (2005) 1725-1737
101. Zwick M., and Burton D.R. HIV-1 neutralization: mechanisms and relevance to vaccine design. Curr. HIV Res. 5 6 (2007) 608-624
102. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., and Parren P.W. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75 22 (2001) 10892-10905
103. Zwick M.B., Kelleher R., Jensen R., Labrijn A.F., Wang M., Quinnan Jr. G.V., Parren P.W., and Burton D.R. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12. J. Virol. 77 12 (2003) 6965-6978
104. Zwick M.B., Jensen R., Church S., Wang M., Stiegler G., Kunert R., Katinger H., and Burton D.R. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol. 79 (2005) 1252-1261